MedTrace Logo

Combination Immunotherapy Targeting Sarcomas

NCT04433221 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-06-16

No results posted yet for this study

Summary

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.

Conditions

  • Sarcoma
  • Osteoid Sarcoma
  • Ewing Sarcoma

Interventions

BIOLOGICAL

Multiple sarcoma-specific CAR-T cells and sarcoma vaccines

1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection

Sponsors & Collaborators

  • The Seventh Affiliated Hospital of Sun Yat-sen University

    collaborator OTHER

  • Shenzhen Children's Hospital

    collaborator OTHER_GOV

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-05-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04433221 on ClinicalTrials.gov